WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H100011
CAS#: 154229-19-3 (Abiraterone)
Description: Abiraterone, also known as CB7598, is the active metabolite of abiraterone acetate, which is an orally active acetate ester of the steroidal compound abiraterone with antiandrogen activity. Abiraterone acetate was approved by the U.S. Food and Drug Administration (FDA) in April 2011. Abiraterone inhibits the enzymatic activity of steroid 17alpha-monooxygenase (17alpha-hydrolase/C17,20 lyase complex), a member of the cytochrome p450 family that catalyzes the 17alpha-hydroxylation of steroid intermediates involved in testosterone synthesis. Administration of this agent may suppress testosterone production by both the testes and the adrenals to castrate-range levels.
Hodoodo Cat#: H100011
Name: Abiraterone
CAS#: 154229-19-3 (Abiraterone)
Chemical Formula: C24H31NO
Exact Mass: 349.24
Molecular Weight: 349.510
Elemental Analysis: C, 82.47; H, 8.94; N, 4.01; O, 4.58
Related CAS #: 154229-18-2 (Abiraterone Acetate) 154229-19-3 (Abiraterone)
Synonym: CB 7598; CB7598; CB-7598; Abiraterone; US trade name: Zytiga.
IUPAC/Chemical Name: (3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridin-3-yl)-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol.
InChi Key: GZOSMCIZMLWJML-VJLLXTKPSA-N
InChi Code: InChI=1S/C24H31NO/c1-23-11-9-18(26)14-17(23)5-6-19-21-8-7-20(16-4-3-13-25-15-16)24(21,2)12-10-22(19)23/h3-5,7,13,15,18-19,21-22,26H,6,8-12,14H2,1-2H3/t18-,19-,21-,22-,23-,24+/m0/s1
SMILES Code: O[C@H]1CC[C@]2(C)[C@@]3([H])CC[C@]4(C)C(C5=CC=CN=C5)=CC[C@@]4([H])[C@]3([H])CC=C2C1
Appearance: white solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >5 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 5.0 | 14.31 |
The following data is based on the product molecular weight 349.51 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Grist E, Attard G. The development of abiraterone acetate for castration-resistant prostate cancer. Urol Oncol. 2015 Jun;33(6):289-294. doi: 10.1016/j.urolonc.2015.03.021. Review. PubMed PMID: 26025264.
2: Petrelli F, Coinu A, Borgonovo K, Cabiddu M, Ghilardi M, Lonati V, Barni S. Enzalutamide After Docetaxel and Abiraterone Acetate Treatment in Prostate Cancer: A Pooled Analysis of 10 Case Series. Clin Genitourin Cancer. 2015 Jun;13(3):193-198. doi: 10.1016/j.clgc.2014.10.006. Epub 2014 Nov 7. Review. PubMed PMID: 25466676.
3: Giacinti S, Bassanelli M, Aschelter AM, Milano A, Roberto M, Marchetti P. Resistance to abiraterone in castration-resistant prostate cancer: a review of the literature. Anticancer Res. 2014 Nov;34(11):6265-9. Review. PubMed PMID: 25368223.
4: Zobniw CM, Causebrook A, Fong MK. Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer. Res Rep Urol. 2014 Aug 5;6:97-105. doi: 10.2147/RRU.S29003. eCollection 2014. Review. PubMed PMID: 25157341; PubMed Central PMCID: PMC4128838.
5: Francini E, Petrioli R, Roviello G. No clear evidence of a clinical benefit of a sequential therapy regimen with abiraterone acetate and enzalutamide. Expert Rev Anticancer Ther. 2014 Oct;14(10):1135-40. doi: 10.1586/14737140.2014.949677. Epub 2014 Aug 19. Review. PubMed PMID: 25135334.
6: Woo HH, Begbie S, Gogna K, Mainwaring PN, Murphy DG, Parnis F, Steer C, Davis ID. Multidisciplinary consensus: a practical guide for the integration of abiraterone into clinical practice. Asia Pac J Clin Oncol. 2014 Sep;10(3):228-36. doi: 10.1111/ajco.12264. Epub 2014 Aug 17. Review. PubMed PMID: 25132163.
7: Nakazawa M, Antonarakis ES, Luo J. Androgen receptor splice variants in the era of enzalutamide and abiraterone. Horm Cancer. 2014 Oct;5(5):265-73. doi: 10.1007/s12672-014-0190-1. Epub 2014 Jul 22. Review. PubMed PMID: 25048254; PubMed Central PMCID: PMC4167475.
8: Boissier E, Loriot Y, Vignot S, Massard C. [Abiraterone acetate (AA): current guidelines of prescription of abiraterone]. Bull Cancer. 2014 Apr;101(4):388-93. doi: 10.1684/bdc.2014.1932. Review. French. PubMed PMID: 24793632.
9: Mostaghel EA, Lin DW. Practical guide to the use of abiraterone in castration resistant prostate cancer. Can J Urol. 2014 Apr;21(2 Supp 1):57-63. Review. PubMed PMID: 24775725; PubMed Central PMCID: PMC4139288.
10: Zhou ZR, Liu SX, Zhang TS, Xia J, Li B. Abiraterone for treatment of metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. Asian Pac J Cancer Prev. 2014;15(3):1313-20. Review. PubMed PMID: 24606458.
